Inflammatory immune response in recipients of transcatheter aortic valves

Cecilia Veraar, MD, a,b Matthias Koschutnik, MD, c Christian Nitsche, MD, c Maria Laggner, PhD, b,d Dominika Polak, PhD, e Barbara Bohle, PhD, e Andreas Mangold, MD, PhD, MBA, * Bernhard Moser, MD, PhD, MBA, d Julia Mascherbauer, MD, c,d and Hendrik J. Ankersmit, MD, MBA b,d

ABSTRACT

Objective: Transcatheter aortic valve implantation (TAVI) is rapidly replacing cardiac surgery due to its minimal invasiveness and practicality. Midterm immunological studies on the biocompatibility of galactose-alpha-1,3-galactose (α-Gal)–carrying bioprosthetic heart valves for TAVI are not available. In this study we investigated whether bioprosthetic heart valves employed for TAVI augment an α-Gal–specific antibody-dependent and antibody-independent immune response 3 months after TAVI implantation.

Methods: This prospective observational study included 27 patients with severe aortic valve stenosis undergoing TAVI and 10 patients with severe mitral valve regurgitation treated with a transcatheter MitraClip (Abbott Laboratories, Abbott Park, Ill) procedure. Blood samples were drawn before and 90 days after treatment at a routine checkup. Serum samples were analyzed using enzyme-linked immunosorbent assay. Serum concentrations of α-Gal–specific immunoglobulin (Ig) G, IgG subclasses and IgE, complement factor 3a, NETosis-specific citrullinated H3, and the systemic inflammation markers soluble suppression of tumorigenicity and interleukin 33 were evaluated.

Results: Three months after TAVI, we found significantly increased serum concentrations of α-Gal–specific IgG3, complement factor complement factor 3a, citrullinated H3 levels, and soluble suppression of tumorigenicity (P = .002, P = .001, P = .025, and P = .039, respectively). Sensitization of α-Gal–specific IgE antibodies occurred in 55% of all patients after TAVI.

Conclusions: Our results indicate that TAVI elicits a midterm, specific humoral immune response against α-Gal and causes an unspecific humoral inflammatory response compared with patients undergoing MitraClip implantation. This observation will lead to a better understanding of postintervention morbidity and the long-term durability of bioprostheses and indicates that caution is appropriate when designing implantation strategies for younger patients. (JTCVS Open 2021;6:85-96)
Transcatheter aortic valve implantations (TAVI) performed by cardiologists and cardiac surgeons will outnumber conventional cardiac operations in the future due to their minimal invasiveness, practicality, and the aging population.1-3 However, midterm immunological studies on the biocompatibility of galactose-α1,3-galactose (α-Gal)–carrying bioprosthetic heart valves (BHV) for TAVI have not been performed so far. The α-Gal epitope is widely accepted as the major elicitor in the pathogenesis of immune activation after xenotransplantation and implantation of glutaraldehyde-fixed BHVs. The relationship between tissue α-Gal–specific immune reactivity and dystrophic calcification, inflammation, and leaflet tearing in bioprostheses in vivo is widely accepted.4-7

Beside BHV-induced α-Gal–specific antibody-dependent humoral immune responses, xenografts activate the classical pathway of the complement system when antibodies bind to antigens such as α-Gal on their surfaces, and thereby trigger C1q to activate C1r and C2s, cleave C4 and C2 and form C4b2a (C3 convertase), and activate complement factor 3a (C3a).8,9

Most recently, another deleterious immune activation process in xenotransplantation has gained prominence, namely the ejection of DNA-histone complexes into the extracellular space from activated neutrophils to form neutrophil extracellular traps (NETs).10,11 Increased NET formation is well known in various clinical conditions, including sepsis, trauma, autoimmune diseases, deep vein thrombosis, atherosclerosis, and thrombotic microangiopathy.12,13

Because multiple nosologies share humoral and cellular activation pathways, we asked whether TAVI increases circulating soluble suppression of tumorigenicity-2 (sST2) and its counterpart interleukin (IL)-33, a known biological alarmin that would serve as an additional biological marker for ongoing inflammatory processes.14-16

In this study, we investigated for the first time whether BHVs employed for TAVI augment an α-Gal–specific humoral immune response of total immunoglobulin (Ig) G, IgG subclasses, and IgE; activate the complement system via C3a; induce citrullinated H3 (CitH3) as a marker for NET formation; and initiate the IL-33/sST2 pathway within 90 days after intervention compared with baseline levels. Patients receiving a MitraClip (Abbott Laboratories, Abbott Park, Ill) procedure served as controls (Figure 1 and Video 1).

METHODS
Ethics Approval
Ethics approval was obtained from the Institutional Ethics Committee of the Medical University of Vienna (EK 2218/2016) during June 2019. All experiments were performed in accordance with the approved ethical guidelines. Written informed consent was obtained from all study participants.

Study Design and Patients
This work was designed as a prospective, observational, single-center study. Twenty-seven consecutive patients with severe aortic valve stenosis and 10 patients with severe mitral valve regurgitation undergoing TAVI or MitraClip procedures between March and August 2019 at the Department of Cardiology of the General Hospital Vienna (Medical University of Vienna) were prospectively analyzed. We excluded pregnant women, patients who were younger than age 18 years, and patients who did not give written informed consent. TAVI was performed in a hybrid operating room under general anesthesia or conscious sedation. Blood samples were drawn before the procedure and 90 days thereafter at a routine clinical check-up.

Enzyme-Linked Immunosorbent Assays
Microtiter plates (Maxisorp, Nunc, Denmark) were coated with Galα1,3-Galβ1−4GlcNAc-BSA (Dextra Laboratories, Reading, United Kingdom). Optimal coating concentrations of each protein were defined in preliminary experiments. Blocking was carried out using assay buffer (2.5 g human serum albumin, 500 mL phosphate buffered saline −/−/Tween 20. 250 μL Tween 20). Sera were diluted in phosphate buffered saline with 0.05% Tween-20 and 0.5% human serum albumin as follows: for IgE, 1:2; for IgG, 1:50; and for IgG1, 3, and 4, 1:20. After sample incubation and washing, the following horseradish peroxidase-conjugated detection antibodies were added: antihuman IgG-Fc (Sigma-Aldrich Corp, St Louis, Mo), IgG subclasses (Sigma-Aldrich Corp) and alkaline phosphatase-conjugated anti-human IgE (BD Bioscience Pharmingen, San Diego, Calif). A color reaction was obtained with peroxidase reagent tetramethylbenzidine (Sigma-Aldrich Corp) and the optical density was read at 450 nm using an absorbance microplate reader (Infinite F50; Tecan, Männedorf, Switzerland).17

A human C3a (BMS2089) enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen; Camarillo, Calif) was used for the quantitative detection of C3a following the manufacturer’s instructions. Serum samples were diluted 1:50000 in assay buffer.

Cayman’s CitH3 (Clone 11D3) ELISA kit (Cayman Chemical, Ann Arbor, Mich) was used to measure citH3 serum concentrations. The

**Abbreviations and Acronyms**

| Abbreviation | Definition |
|--------------|------------|
| α-Gal | galactose-alpha-1,3-galactose |
| BHV | bioprosthesis heart valve |
| C3a | complement factor 3a |
| CitH3 | citrullinated H3 |
| DAPI | 4',6-diamidino-2-phenylindole |
| ELISA | enzyme-linked immunosorbent assay |
| Ig | immunoglobulin |
| IL | interleukin |
| mAb | monoclonal antibody |
| NET | neutrophil extracellular traps |
| NT-proBNP | N-terminal pro-brain natriuretic peptide |
| sST2 | soluble suppression of tumorigenicity-2 |
| TAVI | transcatheter aortic valve implantation |

Video clip is available online.
microwell plate was coated with a monoclonal antibody (mAb) specific for histone H3 (citrullinated at R2, R8, and R17). Sera were added in a 1:2 dilution in assay buffer.

To assess sST2 and IL-33 serum concentrations, commercially available ELISA kits for sST2 (DY523B) and IL-33 (DY3625B) (R&D Systems, Minneapolis, Minn) were used. Sera were diluted 1:20 for sST2 and not diluted for IL-33.

Postinterventional Antithrombotic Therapy

According to our institutional guidelines patients after TAVI/MitraClip procedure received dual antiplatelet therapy combining aspirin and a P2Y12 receptor inhibitor for 3 months, followed by lifelong daily low-dose aspirin (100 mg). In patients with preexisting anticoagulant therapy phenprocoumon or nonvitamin K antagonist oral anticoagulants were continued at a therapeutic dose.

Statistical Analysis

Before the study, we performed a power analysis using G*Power (Heinrich Heine University, Dusseldorf, Germany) according to a prior publication of our study group on α-Gal–specific IgG immune responses after surgical bioprosthetic valve implantation.

To reveal a power of 99%, α = 0.05, 2-sided, using the Wilcoxon-signed-rank test for matched pairs 27 patients undergoing TAVI were required. To calculate the size of the control group, the Wilcoxon-Mann-Whitney U test was used. To reach a power of 84%, α = 0.05, 2-sided, we required 10 patients undergoing the MitraClip procedure.

Graphical methods (histograms) were employed to test normality. Data are reported as mean ± standard deviation for normally distributed data and median (25th percentile, 75th percentile) for nonnormally distributed data. The Kruskal-Wallis rank test and Mann-Whitney U test were used for nonnormally distributed data and t tests were performed for comparisons.
paracrine data. The level of statistical significance was set at .05 (2-tailed P values). Statistical analyses were performed using SPSS software version 26 (IBM-SPSS Inc, Armonk, NY). GraphPad Prism 8 (GraphPad Software, La Jolla, Calif) was employed for data visualization (boxplots and line diagrams). Boxplots were designed as follows: box, first to third quartile; bar, median; whiskers, fifth to 95th percentile; all individual values are presented as dots.

**Data Availability**

All data generated or analyzed during this study are included in this article and Tables E1 through E4.

**RESULTS**

**Demographic and Clinical Data**

In our study, we enrolled 27 TAVI and 10 MitraClip patients, of whom 13 (48.1%) TAVI and 2 (20%) MitraClip patients were women. The median age of all patients was 78 years (range, 75-83 years) for TAVI and 76 years (range, 68-82 years) for MitraClip patients. Thirty-seven percent of all TAVI patients received bovine and 63% received porcine heart valves. The implanted medical devices are described in detail in Table E1. Left-ventricular ejection fraction increased and the concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) decreased statistically significantly in patients receiving TAVI 3 months after intervention (P = .033 and P = .050, respectively). Detailed baseline characteristics and clinical and echo-cardiography data are depicted in Tables 1 and 2. Inflammatory conditions in patients with hyperlipidemia and adult-onset diabetes mellitus are depicted in Tables E2 and E3. None of our patients experienced meat allergy before undergoing the TAVI/MitraClip procedure. Three patients had an allergy to penicillin, 1 patient was allergic to ciprofloxacin and 1 patient was allergic to band-aid.

**Augmented α-Gal–Specific IgG3 3 Months After TAVI**

We investigated whether BHVs of a glutaraldehyde-fixed α-Gal–bearing scaffold installed via TAVI induce α-Gal–specific IgG and IgG subclasses (IgG1, IgG3, and IgG4) before and 3 months after catheter intervention.

We found significantly increased α-Gal–specific IgG3 serum concentrations in patients 3 months after TAVI compared with baseline levels (P = .002). Furthermore, we observed there is a trend toward augmented α-Gal–specific IgG, but not IgG1 or IgG4 (IgG, P = .09; IgG1, P = .34; and IgG4, P = .28). Neither α-Gal–specific IgG nor IgG subclasses (IgG1, IgG3, or IgG4) significantly increased in the MitraClip control cohort (Table 3).

Three months after TAVI, α-Gal–specific IgE serum concentrations did not increase statistically significant (P = .28). However, IgE sensitization occurred in 55% of all TAVI patients. Differences in α-Gal–specific antibodies between bovine and porcine heart valves for TAVI are shown in Table E4.

**Significantly Increased C3a in TAVI Patients 3 Months After Intervention**

The role of the complement system as innate immunity in xenograft rejection beyond naturally occurring cytotoxic α-Gal–specific mAbs is well described. Activation of the classical complement pathway is caused by the binding of antibodies to antigens and is the major mechanism of xenograft rejection. We investigated whether BHVs for TAVI trigger systemic complement activation in vivo. We measured C3a because this protein is the hinge point of the alternative and lectin complement activation pathway.

Three months after TAVI, C3a levels were significantly increased compared with baseline levels (baseline, 7.8 μg/
mL; range, 3.2-37.9 μg/mL vs 3-month TAVI, 37.2 μg/mL; range, 4.6-89.3 μg/mL; \( P = .001 \). In contrast, patients receiving the MitraClip procedure had lower C3a serum concentrations after intervention compared with baseline values (baseline, 16.5 μg/mL; range, 5.7-48.5 μg/mL vs 3-month MitraClip, 6.3 μg/mL; range, 3.1-45.3 μg/mL; \( P = .130 \)). These data are evidence that the implantation of glutaraldehyde-fixed biological scaffolds augments the activation of complement pathways in vivo (Figure 2, A and B). There were no differences in C3a serum concentrations between bovine and porcine heart valves for TAVI (Table E4).

**Significantly Increased CitH3 Serum Concentrations, an Indicator of Granulocyte-Specific NETosis, 3 Months After TAVI and MitraClip Implantation**

Neutrophils are an important cellular component of innate immunity. They play a critical role in microbial clearance, activation of other immune cells, and tissue damage and repair, and contribute to coagulation. Neutrophils are also involved in xenograft rejection. The presence of CitH3 in the serum is an accepted biological marker for the detection of granulocyte-specific NETosis.\(^\text{18}\) Three months after TAVI, CitH3 was significantly higher than baseline levels (baseline, 2.7 ng/mL; range, 1.1-4.2 ng/mL vs 3-month TAVI, 3.9 ng/mL; range, 1.3-9.7 ng/mL; \( P = .025 \)). Similar to the TAVI cohort, MitraClip patients also had significantly elevated CitH3 serum concentrations 3 months postintervention (baseline, 1.7 ng/mL; range, 1.5-5.2 ng/mL vs 3-month MitraClip, 2.9 ng/mL; range, 1.5-7.2 ng/mL; \( P = .039 \)). These data indicate that TAVI, as well as MitraClip (to a lower extent) elicit NETosis in vivo (Figure 2, C and D). There were no differences in citH3 serum concentrations between bovine and porcine heart valves for TAVI (Table E4).

**Significantly Increased sST2 but Not IL-33 Levels 3 Months After TAVI Implantation**

Secretion of sST2 is triggered by the cytokines IL-1α, IL-1β, and IL-6 and contributes to the proinflammatory phase of systemic inflammation.\(^\text{19}\) IL-33 itself can upregulate

---

**TABLE 2. Clinical and echocardiographic data**

| Variable                        | TAVI | MitraClip* |
|---------------------------------|------|------------|
| **Clinical**                    |      |            |
| NT-proBNP (pg/mL)               | 1716.0 (916.7, 4764.5) | 2979.5 (1107.0, 7320.7) |
| Creatinine (mg/dL)              | 1.0 (0.93, 1.6) | 1.1 (0.95, 1.8) |
| NYHA functional class ≥III      | 22 (81.5) | 7 (70) |
| **Echocardiographic parameters**|      |            |
| LVEF ≥55%                       | 14 (51.9) | 4 (40) |
| LVEF 54%-45%                    | 5 (18.5) | 1 (10) |
| LVEF 44%-30%                    | 4 (14.8) | 4 (40) |
| LVEF <30%                       | 4 (14.8) | 1 (10) |
| sPAP (mm Hg)                    | 64.0 (51.2, 78.2) | 41.0 (30.0, 51.0) |
| AV PPG                          | 76.0 (65.5, 111.0) | 16.5 (12.0, 26.5) |
| AV MPG                          | 45.5 (41.7, 62.5) | 9.5 (6.0, 15.0) |
| AV Vmax                         | 4.6 (4.0, 5.5) | 1.8 (1.6, 2.2) |
| AVA (cm²)                       | 0.7 (0.6, 0.85) | – |

Significant \( P \) values were written in boldface. Values are presented as median (25th percentile, 75th percentile) or n (%). \( TAVI \), Transcatheter aortic valve replacement; \( NT\)-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; \( LVEF \), left ventricular ejection fraction; \( sPAP \), systolic pulmonary artery pressure; \( AV \), aortic valve; \( PPG \), peak pressure gradient; \( MPG \), mean pressure gradient; \( Vmax \), maximum velocity; \( AVA \), aortic valve area. *Abbott Laboratories, Abbott Park, Ill.
expression of sST2. Aside from acting as a decoy receptor for IL-33, sST2 is believed to exhibit its anti-inflammatory capacity directly via inhibition of Toll-like receptor signalling, ultimately resulting in the downregulation of nuclear factor-kappa B in macrophages. Currently sST2 and IL-33 are emerging as markers of systemic inflammation with prognostic capacity in many clinical entities (eg, polytrauma, sepsis, and food...

FIGURE 2. Significantly increased serum concentration of complement factor 3a (C3a), citrullinated H3 (CitH3), and soluble suppression of tumorigenicity-2 (sST2) 3 months after transcatheter aortic valve implantation (TAVI) compared with baseline levels. A, Three months after TAVI, C3a serum concentrations were significantly elevated compared to baseline levels. B, C3a serum concentrations did not increase 3 months after MitraClip (Abbott Laboratories, Abbott Park, Ill). C and D, Three months after TAVI and MitraClip, CitH3 serum concentrations were significantly upregulated compared with baseline levels. E and F, In TAVI patients, but not MitraClip patients, sST2 serum concentrations were significantly higher 3 months after intervention. For statistical analyses of serum concentrations between baseline levels and 3 months after TAVI or MitraClip the Wilcoxon matched-pairs signed-rank test was used.
allergy).14,15,20 Here, TAVI increased sST2 significantly (baseline, 2.9 ng/mL; range, 2.3-3.4 ng/mL vs 3-month TAVI, 4.3 ng/mL; range, 2.3-4.7 ng/mL; \( P = .039 \)) compared with MitraClip implantation (baseline, 3.7 ng/mL; range, 2.5-4.9 ng/mL vs 3-month MitraClip, 3.2 ng/mL; range, 2.5-4.8 ng/mL; \( P = .09 \)). IL-33 did not increase 3 months after TAVI or MitraClip compared with baseline levels (baseline, 25.58 pg/mL; range, 14.36-46.15 pg/mL vs 3-month TAVI, 25.01 pg/mL; range, 18.044-3.36 pg/mL; \( P = .728 \) and baseline, 55.39 pg/mL; range, 11.79-806.0 pg/mL vs 3-month MitraClip, 17.92 pg/mL; range, 10.68-516.7 pg/mL; \( P = .670 \)). These data show that \( \alpha \)-Gal–bearing biological scaffolds induce a systemic host immune activation relevant to the compensatory anti-inflamatory response syndrome and allergic immune response (Figure 2, E and F). There were no differences in sST2 serum concentrations between bovine and porcine heart valves for TAVI (Table E4).

Clinical Outcome Data

Within 3 months after intervention 5 TAVI patients were readmitted to the hospital. Three patients were readmitted due to postintervention complications: One patient required vascular surgery of a pseudoaneurysm of the femoral artery after arterial puncture. Another patient developed a third-degree atrioventricular block and required a pacemaker implantation. Another patient was readmitted for gastrointestinal bleeding after receiving therapeutic anticoagulant therapy and aspirin. This patient received additional thromboembolic therapy due to atrial fibrillation and a coronary artery stent. The 2 noncardiology reasons for readmission were occurrence of a pseudoaneurysm in the left cubital artery after hemodialysis shunt graft implantation and dyspnea in a patient with a bronchial carcinoma. One MitraClip patient was readmitted for dyspnea. None of all included patients died within 3 months after TAVI/MitraClip intervention.

DISCUSSION

Here we demonstrate that TAVI elicits an up-regulation of \( \alpha \)-Gal–specific IgG3 mAbs, activates the complement system, induces NET formation, and causes increased sST2/IL-33 cytokine spillage in vivo.

These data provide evidence that \( \alpha \)-Gal–bearing medical devices are an ongoing inflammatory trigger. The link between \( \alpha \)-Gal–specific antibodies and humoral valve destruction has seemed obvious since 2005, but until recently, there was mere conjecture by informed surgeons and allergologists.5,21 Hawkins and colleagues22 recently described 2 patients who underwent implantation of a BHV and developed a postoperative meat allergy associated with an \( \alpha \)-Gal–specific IgE immune response. Both patients developed premature degeneration of the bioprosthesis that necessitated reoperation and implantation of a mechanical valve in the aortic position.22 This was the first clinical proof that \( \alpha \)-Gal on commercial BHVs and de novo development of \( \alpha \)-Gal–specific IgE antibodies can lead to biovalve degeneration.

Platts Mills, FRS, was among the first allergologists to propagate the idea that formation of \( \alpha \)-Gal–specific IgE is phenomenologically related to the development of meat allergy.23 Kollmann and colleagues17 extended this insight by showing that meat allergy is also associated with increased IgG, IgG1, and IgG3 directed against \( \alpha \)-Gal. Relevant to the above findings is the notion that \( \alpha \)-Gal–specific monoclonal antibodies remain rather stable in healthy humans.24 In this study, we provide evidence that, similar to surgically implanted bioprostheses,4,5 TAVI causes \( \alpha \)-Gal–specific IgG3 production as well as de novo production of \( \alpha \)-Gal–specific IgE. None of our older patients developed the symptoms described in meat-allergic patients.

The complement system and NETosis are known to interact reciprocally.18 Opsonized antigens such as \( \alpha \)-Gal are recognized by complement receptors on neutrophils, which subsequently induce NETosis, whereas neutrophils activate complement factors, especially the anaphylatoxins C3a and C5a, which can further alarm the immune system.25

Although our study found an \( \alpha \)-Gal–induced enhancement of the complement system and NET formation within 3 months after TAVI, both systems were already known to be activated in stenotic aortic valves.26 Helske and colleagues27 found both elevated anaphylatoxin C3a and C5a levels and increased anaphylatoxin receptors, in particular C3a receptor, in stenotic aortic valves in contrast to nonsenotic valves.27

Implanted foreign bodies comprising biological scaffolds for TAVI and mechanical devices for MitraClip are both lifesaving interventions with an increased risk of thrombogenicity and bleeding by inducing flow alterations.28,29 NETs activate the coagulation cascade directly and stimulate thrombosis in a platelet-dependent manner.29,30 In our study, demonstrated enhanced citH3 serum concentrations in TAVI and MitraClip patients and thereby emphasize the importance of therapeutic antithrombotic therapy with either dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitors or anticoagulation in a therapeutic dose for patients after TAVI and MitraClip procedures.31

We also found that, in parallel to the humoral immune response, sST2 is significantly increased after TAVI implantation in the presence of significantly improved left ventricular function (according to New York Heart Association functional classification) and lower levels of NT-proBNP. sST2 is a biomarker of adverse outcomes after myocardial infarction and heart failure as well as systemic inflammatory conditions.19,32,33 Our data, namely the increased sST2 levels 3 months after TAVI implantation with concomitantly reduced cardiac strain (as determined by lower levels of NT-proBNP), make it clear that sST2 may serve as a
marker of inflammation rather than heart failure in TAVI patients.

In 1987, Galili and colleagues reported that the \( \alpha \)-Gal epitope is present on cells of all mammals except for humans and Old World monkeys. However, valve hemodynamic deterioration was associated with porcine tissue valve implantation in patients undergoing surgical valve implantation. In our study, we did not find any differences in cytokine serum concentrations and anti-Gal antibodies between patients receiving bovine compared with porcine BHVs for TAVI. We therefore assume that porcine and bovine biological scaffolds display similar immunogenic potential. Further studies with higher sample sizes are warranted to evaluate species-specific immune responses elicited by xenogenic implants.

The link between \( \alpha \)-Gal–specific inflammation and valve degeneration was determined through experimental work. Animal studies reported enhanced tissue calcification in rats and mice receiving \( \alpha \)-Gal–positive xenogenic tissue implantation. Our study group confirmed in humans short and midterm degeneration of \( \alpha \)-Gal–bearing cells of surgical BHVs through exposure to the human blood circuit. Explanted cells were double fluorescence labeled with IB4 against \( \alpha \)-Gal residues and 4',6-diamidino-2-phenylindole (DAPI) against DNA to stain for nucleated cells. A BHV explanted 1 week after implantation contained IB4/DAPI positive cells within the collagen matrix. In 2 patients, who underwent reoperation after 12 months, porcine tissue showed a complete lack of IB4/DAPI positive cells.

Clinical studies confirmed surgical BHV degeneration 15 years postoperatively in 60\% to 70\% of all patients older than age 75 years, whereas 100\% of all implanted BHVs fail within 5 years in patients younger than age 35 years. Nevertheless, the 2017 Guidelines of the American Heart Association and the American College of Cardiology lowered the recommended age limit of BHV implantation to 50 years due to improved hemodynamic status, a lower risk of thromboembolic complications, and the absence of need for lifelong anticoagulant therapy compared with mechanical heart valves. Besides, modern percutaneous valve-in-valve technologies provide less-invasive alternatives to treat potential BHV degeneration.

We are convinced that TAVI will supersede surgical valve implantation in the future. Based on our data and data produced by others, currently utilized \( \alpha \)-Gal–bearing biological scaffolds must be optimized by the commercial medical device industry. Several promising techniques have been reported to potentially increase the longevity of BHVs. Already in 2013, treatment of BHVs with \( \alpha \)-galactosidase was used to effectively remove \( \alpha \)-Gal epitopes from both bovine and porcine tissues. Naso and colleagues introduced a preservation technique (ie, FACTA) that guarantees improved tissue biocompatibility by inactivating up to 95\% of the \( \alpha \)-Gal epitopes and thereby reducing the propensity of BHVs to calcify.

Besides preservation techniques, there is growing interest in developing Gal-free BHVs from Gal-knockout pigs. Recently, Rahmani and colleagues used Gal-knockout pigs in engineering BHVs out of porcine pericardial leaflets with excellent hemodynamic parameters, long-term durability, and no thrombogenicity in a sheep model. Because BHVs for TAVI must be flexible, Gal-knockout pericardium xenografts seem to be favorable BHVs for TAVI to replace surgical aortic valve replacement in younger and lower-risk patients. Most recently, promising results of ongoing research concerning tissue-engineered heart valves for TAVI based on decellularized matrix in the pulmonary and aortic tissue were published.

Our study has several limitations due to the limited sample size. We compared 2 different pathologies and surgical interventions: patients with aortic stenosis undergoing TAVI and patients with severe mitral regurgitation undergoing the MitraClip procedure. Due to the small sample size, we might have missed important demographic and immunological differences between groups. Further, we did not include patients after surgical aortic valve replacement as a control group. We could only draw our conclusions on similarities in the inflammatory response after surgical aortic valve replacement and TAVI patients due to prior research of our study group. Further, according to the current guidelines and institutional standards of the TAVI procedure, the median age of our study cohort was 78 years. We therefore cannot draw conclusions on systemic inflammatory responses in younger patients. In addition, determining immunological changes after prolonged follow-up periods might help to reveal whether these inflammatory changes will persist and have any effects on clinical outcomes and valve durability.

**CONCLUSIONS**

TAVI significantly improved left-ventricular function and reduced clinical symptoms in patients within 3 months after intervention. We present evidence that TAVI implantation elicits an \( \alpha \)-Gal-specific and unspecific humoral systemic inflammation that may influence BHV durability. We believe that the medical community should be cautioned against the uncritical lowering of age limits in recipients of \( \alpha \)-Gal–bearing TAVI devices.

**Conflict of Interest Statement**

The authors reported no conflicts of interest.

The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
References

1. Baumgartner H, Falk V, Bas JI, De Bonis M, Hamm C, Holm P, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-91.

2. Siontis GCM, Overhoudt P, Cahill TJ, Modeine T, Prendergast B, Praz F, et al. Transthoracic aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J. 2019;40:3143-53.

3. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2017;376:1895-905.

4. Konakci KZ, Bohle B, Blumer R, Hoetzeneyer K, Roth G, Moser G, et al. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest. 2005;35:17-23.

5. Mangold A, Szeraff T, Hoetzeneyer K, Hacker S, Lichtenauer M, Niederpoldet T, et al. Alpha-Gal specific IgG immune response after implantation of bioprostheses. Thorac Cardiovasc Surg. 2009;57:191-5.

6. Park CS, Oh SS, Kim YE, Choi SY, Lim HG, Ahn H, et al. Anti-alpha-Gal antibody response following xenogenic heart valve implantation in adults. J Heart Valve Dis. 2013;22:222-9.

7. Lim HG, Choi SY, Yoon EJ, Kim SH, Kim YJ. In vivo efficacy of alpha-galactosidase as possible promise for prolonged durability of bioprosthetic heart valve using alpha1,3-galactosyltransferase knockout mouse. Tissue Eng Part A. 2013;19:2339-48.

8. Zhou H, Hara H, Cooper DKC. The complex functioning of the complement system in xenotransplantation. Xenotransplantation. 2019;26:e12517.

9. Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest. 2017;127:2492-504.

10. You HJ, Kim HE, Gu YV, Lee SB, Lee HJ, Hwang HY, et al. Porcine endothelium induces DNA-histone complex formation in human whole blood: a harmful effect of histone on coagulation and endothelial activation. Xenotransplantation. 2016;23:464-71.

11. Wang HT, Maeda A, Sakai R, Lo PC, Takakura C, Jiaravuthisan P, et al. Human...
(pulsta valve) implantation using knitted nitinol wire backbone and trileaflet alpha-Gal-free porcine pericardial valve in the native right ventricular outflow tract. *Circ Cardiovasc Interv.* 2018;11:e006494.

46. Belluschi I, Buzzatti N, Gastiglioni A, Bonis MD, Montorfano M, Alfieri O, et al. Severe aortic stenosis in the young, with or without bicuspid valve: is transcatheter aortic valve implantation the first choice? *Eur Heart J Suppl.* 2020;22(Suppl L):L1-5.

**Key Words:** TAVI, alpha Gal, NETosis, complement activation, bioprosthetic heart valves, MitraClip, ST2
### TABLE E1. Implanted medical devices for transcatheter aortic valve implantation and MitraClip (Abbott Laboratories, Abbott Park, Ill)

| Device                                      | n  | Bovine/porcine |
|---------------------------------------------|----|----------------|
| Transcatheter heart valves                  |    |                |
| Edwards, Sapien 3 Ultra transcatheter valve | 10 | Bovine         |
| Medtronic, CoreValve Evolut PRO transcatheter aortic valve | 4  | Porcine        |
| Boston Scientific, ACURATE neo Aortic Valve | 8  | Porcine        |
| Abbott, Portico valve                       | 1  | Porcine        |
| St Jude Medical, Portico valve              | 4  | Porcine        |
| MitraClip devices                           |    |                |
| Edwards, PASCAL transcatheter valve repair system | 2  |                |
| Abbott, MitraClip XTR Clip Delivery System  | 5  |                |
| Abbott, MitraClip NTR Clip Delivery System  | 3  |                |

### TABLE E2. Baseline inflammatory conditions in patients with hyperlipidemia and adult-onset diabetes mellitus

|                  | Yes | No  | P value |
|------------------|-----|-----|---------|
| IgG (OD)         | 11.6 (3.2, 14.9) | 11.7 (5.1, 15.8) | .710 |
| IgG1 (OD)        | 27.3 (8.5, 70.6) | 38.2 (15.1, 70.8) | .477 |
| IgG3 (OD)        | 2.3 (2.0, 6.8)  | 2.0 (1.7, 4.8)   | .115 |
| IgE (OD)         | 0.5 (0.4, 2.0)  | 0.9 (0.3, 1.6)   | .988 |
| sST2 (ng/mL)     | 2.8 (2.2, 3.5)  | 3.4 (2.6, 4.3)   | .414 |
| c3a (µg/mL)      | 12.1 (3.1, 30.5) | 10.5 (3.8, 53.7) | .496 |
| citH3 (ng/mL)    | 2.8 (1.4, 6.2)  | 2.8 (1.1, 4.2)   | .567 |

|                  | Yes | No  | P value |
|------------------|-----|-----|---------|
| Adult-onset diabetes mellitus                  |     |     |         |
| IgG (OD)        | 12.6 (6.6, 14.8) | 11.7 (4.6, 15.6) | .832 |
| IgG1 (OD)       | 33.7 (19.3, 70.6) | 38.2 (2.9, 70.7) | .564 |
| IgG3 (OD)       | 2.1 (1.8, 3.9)   | 2.4 (1.8, 6.4)   | .496 |
| IgE (OD)        | 0.6 (0.4, 1.7)   | 0.5 (0.3, 1.8)   | .564 |
| sST2 (ng/mL)    | 3.2 (2.6, 4.4)   | 2.7 (0.0, 3.5)   | .330 |
| c3a (µg/mL)     | 12.1 (4.3, 53.7) | 10.5 (3.2, 34.3) | .523 |
| citH3 (ng/mL)   | 2.8 (1.3, 6.7)   | 2.8 (1.4, 5.1)   | .542 |

Values are reported as median (25th percentile, 75th percentile). Ig, Immunoglobulin; OD, optical density; sST2, soluble suppression of tumorigenicity-2; c3a, complement factor 3a; citH3, citrullinated H3.
### TABLE E3. Fold increase of serum cytokine levels and galactose-alpha-1,3-galactose–specific antibodies in patients with hyperlipidemia and adult-onset diabetes mellitus

| Hyperlipidemia | Yes                  | No                  | P value |
|----------------|----------------------|---------------------|---------|
| IgG            | 1.7 (−19.5, 56.9)    | −3.1 (−22.5, 19.9)  | .386    |
| IgG1           | −8.1 (−52.1, 16.7)   | −1.5 (−48.6, 30.5)  | 1.000   |
| IgG3           | 40.0 (−13.2, 92.5)   | 13.5 (−3.5, 47.7)   | .496    |
| IgE            | 16.0 (−34.1, 63.7)   | −2.0 (−17.6, 72.7)  | .781    |
| sST2           | 25.3 (−20.5, 74.2)   | −1.9 (−28.5, 38.6)  | .224    |
| c3a            | 29.3 (−66.0, 62.0)   | 3.4 (−16.0, 48.5)   | .926    |
| citH3          | 20.6 (−17.9, 61.8)   | 11.4 (−17.0, 68.1)  | .710    |

Adult-onset diabetes mellitus

| IgG            | 5.1 (−20.6, 52.4)    | −3.5 (−22.2, 20.8)  | .564    |
| IgG1           | 0.0 (−36.9, 10.9)    | −11.4 (−49.9, 47.0) | .801    |
| IgG3           | 51.0 (−3.9, 155.0)   | 13.5 (−17.9, 47.7)  | .145    |
| IgE            | 30.3 (−17.1, 30.3)   | −2.0 (−61.3, 39.2)  | .083    |
| sST2           | 26.1 (−24.8, 48.9)   | −3.5 (−22.2, 20.8)  | .704    |
| c3a            | 20.4 (−57.6, 52.1)   | 3.4 (−21.0, 63.4)   | 1.000   |
| citH3          | 33.9 (−12.8, 72.1)   | 11.4 (−19.7, 40.0)  | .391    |

Values are reported as median (25th percentile, 75th percentile). Ig, Immunoglobulin; OD, optical density; sST2, soluble suppression of tumorigenicity-2; c3a, complement factor 3a; citH3, citrullinated H3.

### TABLE E4. Differences in cytokine serum concentrations and galactose-alpha-1,3-galactose–specific antibodies between bovine and porcine heart valves for TAV1

| Variable | Bovine      | Porcine     | P value |
|----------|-------------|-------------|---------|
| IgG      | 8.3 (−3.8 to 141.8) | 1.4 (−20.6 to 53.9) | .315    |
| IgG1     | −5.6 (−40.6 to 46.1) | 3.1 (−98.1 to 65.1) | .953    |
| IgG3     | 43.5 (−11.2 to 101.8) | 37.5 (−1.6 to 156.7) | .841    |
| IgE      | −3.5 (−58.6 to 84.3) | 3.1 (−98.1 to 65.1) | .514    |
| sST2     | 19.7 (−12.8 to 32.7) | 21.2 (−17.2 to 35.2) | .777    |
| c3a      | −9.5 (−12.8 to 52.7) | 45.5 (10.0 to 67.3) | .056    |
| citH3    | −0.4 (−65.7 to −33.7) | 11.1 (−14.1 to 74.0) | .176    |

Values are reported as median (interquartile range). Ig, Immunoglobulin; sST2, soluble suppression of tumorigenicity-2; c3a, complement factor 3a; citH3, citrullinated H3.